Novo Nordisk A/S - Share repurchase programme


On 7 August 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an
amount up to DKK 2.4 billion in the period from 10 August 2009 to 18
December 2009.

Since the announcement as of 16 November 2009, the following
transactions have been made under the programme:


                          Number of    Average     Transaction value,
                           shares   purchase price        DKK
Accumulated, last
announcement              5,464,099                     1,746,802,641
16 November 2009             70,000       328.7680         23,013,760
17 November 2009             61,500       327.3010         20,129,012
18 November 2009             70,000       329.2998         23,050,986
19 November 2009             68,000       329.5300         22,408,040
20 November 2009             60,000       330.7910         19,847,460
Accumulated under the
programme                 5,793,599                     1,855,251,898


With the transactions stated above, Novo Nordisk owns a total of
30,509,977 treasury shares, corresponding to 4.9% of the share
capital. The total amount of shares in the company is 620,000,000
including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,000
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.

Further information:

Media:                 Investors:

Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
ekh@novonordisk.com    mlau@novonordisk.com

                       Kasper Roseeuw Poulsen
                       Tel: (+45) 4442 4471
                       krop@novonordisk.com

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   hrmm@novonordisk.com


 Company Announcement no 69 / 2009




http://hugin.info/2013/R/1356600/329665.pdf


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.